| |
CME Program and Slide Decks
Thrombosis Scientific Poster Session and Clinical Update
This accredited program is based on presentations given on Sunday, December 9, 2007 at the Atlanta Marriott Marquis Hotel, Atlanta, Georgia. Clinicians from the American Society of Hematology Annual Meeting and Exposition (ASH) were in attendance.
Please select the Presentations tab from above to view the accredited video and slide presentations. In order to receive credit, the CME test and evaluation must be completed and returned via fax or sent via email to MER. We are also offering the opportunity to view and download the faculty-selected posters (20) and abstract booklet. They can be accessed here.
PURPOSE STATEMENT
Given the ongoing developments in the management of thrombosis, it is critical to provide education regarding recently presented or published trial results. This CME program is an ideal forum for updating and informing the hematology community on venous thromboembolism prevention and treatment, considered crucial for optimum patient care. Our expert faculty selected 20 clinical trials, which have been presented or published at recent meetings; these trials provide critical new data and serve as the clinical foundation for discussion of new evidence in the management of thrombosis. The trials include recent data on new oral anticoagulants, such as direct inhibitors of Factor Xa and direct thrombin inhibitors.
CHAIRS
 |
Jack E. Ansell, MD (CV)
Professor of Medicine
Vice Chairman, Department of Medicine
Boston University School of Medicine
Boston, MA
|
 |
Alexander G. G. Turpie, MD, FRCP, FRCPC (CV)
Professor of Medicine
McMaster University
Hamilton, Ontario, Canada
|
DISCLOSURES
Jack E. Ansell, MD is a consultant for Bayer HealthCare, Johnson & Johnson, Bristol-Myers Squibb
Alexander GG Turpie, MD, FRCP, FRCPC is a consultant for Bayer HealthCare, Johnson & Johnson, Astellas, Portola, Sanofi-Aventis
LEARNING OBJECTIVES
|
1. |
Identify unmet needs with current treatment |
|
2. |
Discuss the data, evidence, and implications of landmark trials in thrombosis management |
|
3. |
Understand the role of Factor Xa as a target for preventing and treating thrombosis |
|
4. |
Realize practical applications for the use of anti-thrombotics based on current evidence and guidelines
|
PHYSICIAN ACCREDITATION
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Medical Education Resources and the Center for Healthcare Education Medical Education Resources is accredited by the ACCME to provide continuing medical education for physicians.
CREDIT DESIGNATION
Medical Education Resources designates this educational activity for a maximum of 2.0 AMA PRA Category 1 credit(s) TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
There are no fees/costs associated with this program.
CME credit will be valid through January 16, 2009.
|
